Previous 10 | Next 10 |
home / stock / sdmhf / sdmhf news
Founded in 1870, Sartorius Stedim Biotech S.A. is a subsidiary of Sartorius AG. The company is a leading international backend partner for the biopharmaceutical industry and laboratories. Sartorius Stedim is partnering with McMaster University for advanced research in biomanufactu...
McMaster, Sartorius Stedim Biotech team up to advance biomanufacturing processes with next-gen tech PR Newswire HAMILTON, ON and AUBAGNE, France , Aug. 23, 2021 /PRNewswire/ -- Sartorius Stedim Biotech, a leading international partner of the biopharmaceutical...
The life science company Sartorius (OTCPK:SARTF), through its subgroup Sartorius Stedim Biotech (OTCPK:SDMHF), acquired cell culture specialist Xell AG headquartered in Bielefeld, Germany. Xell AG develops, produces, and markets media and feed supplements for cell cultures, especially for man...
Sartorius Stedim Biotech acquires cell culture specialist Xell AG - Extension of the Sartorius Stedim Biotech cell culture media business with a focus on media for gene therapeutics and vaccines - Significant expansion of capacities for manufacturing dry powder and liquid me...
The following slide deck was published by Sartorius Stedim Biotech S.A. in conjunction with their 2021 Q1 earnings call. For further details see: Sartorius Stedim Biotech S.A. 2021 Q1 - Results - Earnings Call Presentation
Sartorius Stedim Biotech S.A. (SDMHF) Q2 2021 Earnings Conference Call July 21, 2021, 09:30 AM ET Company Participants Joachim Kreuzburg - CEO Rainer Lehmann - CFO, Member of Executive Board Conference Call Participants Patrick Wood - Bank of America Michael Leuchten - UBS Paul Knight - KeyBa...
Sartorius Stedim Biotech S.A. (SDMHF): H1 GAAP EPS of €3.49.Revenue of €1.35B (+55.% Y/Y)Press Release For further details see: Sartorius Stedim Biotech S.A. reports H1 results
Half-year results of Sartorius Stedim Biotech - Sales revenue up 61.1 percent to 1,352 million euros; underlying EBITDA margin 36.1 percent - Dynamic organic growth; added momentum from pandemic-related business and acquisitions - Forecast for 2021 raised yet again at th...
Sartorius Stedim Biotech provides preliminary first-half financial key figures and raises forecast for 2021 Sartorius Stedim Biotech announces today that it expects strong first-half performance and raises its forecast for the full year of 2021. Disclosure of inside informat...
Sartorius Stedim Biotech strengthens product portfolio for cell and gene therapies by acquiring a majority stake in CellGenix - Portfolio expanded by cell culture components, such as growth factors, cytokines, and media - CellGenix site in Freiburg to be expanded into a cent...
News, Short Squeeze, Breakout and More Instantly...
Sartorius Stedim Biotech Company Name:
SDMHF Stock Symbol:
OTCMKTS Market:
Nine-month results 2022 of Sartorius Stedim Biotech PR Newswire Sales revenue up 17.0 percent in constant currencies, underlying EBITDA margin at 35.0 percent Overall market situation characterized by innovations and strong growth drivers; current development as ex...
Sartorius Stedim Biotech to acquire Albumedix, strengthening its portfolio of innovative advanced therapy solutions PR Newswire UK-based Albumedix Ltd. is a leader in the field of recombinant albumin-based solutions and a highly innovative and profitable company Re...
Half-year results 2022 of Sartorius Stedim Biotech PR Newswire AUBAGNE, France , July 21, 2022 Sales revenue up 22.1 percent in constant currencies, underlying EBITDA margin 35.2 percent 2022 outlook confirmed: Sales revenue expected...